Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators.

Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30.

2.

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators.

Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25.

3.

Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.

Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T.

Clin Pharmacokinet. 2019 Oct 4. doi: 10.1007/s40262-019-00820-x. [Epub ahead of print]

PMID:
31583611
4.

The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.

Lavall D, Jacobs N, Mahfoud F, Kolkhof P, Böhm M, Laufs U.

Biochem Pharmacol. 2019 Oct;168:173-183. doi: 10.1016/j.bcp.2019.07.001. Epub 2019 Jul 5.

PMID:
31283930
5.

Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.

Kolkhof P, Pook E, Pavkovic M, Kretschmer A, Buchmüller A, Tinel H, Delbeck M, Mondritzki T, Wasnaire P, Dinh W, Truebel H, Hüser J, Schmeck C.

J Cardiovasc Pharmacol. 2019 Jul;74(1):44-52. doi: 10.1097/FJC.0000000000000677.

PMID:
31274842
6.

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress.

González-Blázquez R, Somoza B, Gil-Ortega M, Martín Ramos M, Ramiro-Cortijo D, Vega-Martín E, Schulz A, Ruilope LM, Kolkhof P, Kreutz R, Fernández-Alfonso MS.

Front Pharmacol. 2018 Oct 9;9:1131. doi: 10.3389/fphar.2018.01131. eCollection 2018.

7.

Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.

Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Radtke M, Platzek J, Lovis K, Rohde G, Schwarz T.

Drug Metab Dispos. 2018 Nov;46(11):1546-1555. doi: 10.1124/dmd.118.083337. Epub 2018 Aug 31.

PMID:
30171161
8.

Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.

Bonnard B, Pieronne-Deperrois M, Djerada Z, Elmoghrabi S, Kolkhof P, Ouvrard-Pascaud A, Mulder P, Jaisser F, Messaoudi S.

J Mol Cell Cardiol. 2018 Aug;121:124-133. doi: 10.1016/j.yjmcc.2018.06.008. Epub 2018 Jul 6.

PMID:
29981797
9.

Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.

Lachaux M, Barrera-Chimal J, Nicol L, Rémy-Jouet I, Renet S, Dumesnil A, Wecker D, Richard V, Kolkhof P, Jaisser F, Ouvrard-Pascaud A, Mulder P.

Diabetes Obes Metab. 2018 Oct;20(10):2399-2407. doi: 10.1111/dom.13393. Epub 2018 Jun 27.

PMID:
29862614
10.

Remote Left Ventricular Hemodynamic Monitoring Using a Novel Intracardiac Sensor.

Mondritzki T, Boehme P, White J, Park JW, Hoffmann J, Vogel J, Kolkhof P, Walsh S, Sandner P, Bischoff E, Dinh W, Hüser J, Truebel H.

Circ Cardiovasc Interv. 2018 May;11(5):e006258. doi: 10.1161/CIRCINTERVENTIONS.117.006258.

PMID:
29748220
11.

Corticosteroid receptors adopt distinct cyclical transcriptional signatures.

Le Billan F, Amazit L, Bleakley K, Xue QY, Pussard E, Lhadj C, Kolkhof P, Viengchareun S, Fagart J, Lombès M.

FASEB J. 2018 Oct;32(10):5626-5639. doi: 10.1096/fj.201800391RR. Epub 2018 May 7.

PMID:
29733691
12.

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.

Barrera-Chimal J, Estrela GR, Lechner SM, Giraud S, El Moghrabi S, Kaaki S, Kolkhof P, Hauet T, Jaisser F.

Kidney Int. 2018 Jun;93(6):1344-1355. doi: 10.1016/j.kint.2017.12.016. Epub 2018 Mar 13.

PMID:
29548765
13.

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.

Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, Brix S, Betz IR, Schupp M, Foryst-Ludwig A, Klopfleisch R, Stawowy P, Houtman R, Kolkhof P, Kintscher U.

Hypertension. 2018 Apr;71(4):599-608. doi: 10.1161/HYPERTENSIONAHA.117.10360. Epub 2018 Feb 5.

PMID:
29437893
14.

New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions.

Mondritzki T, Boehme P, Schramm L, Vogel J, Mathar I, Ellinghaus P, Kolkhof P, Bischoff E, Hüser J, Dinh W, Sandner P, Truebel H.

Eur J Appl Physiol. 2018 Jan;118(1):195-203. doi: 10.1007/s00421-017-3761-3. Epub 2017 Nov 20.

PMID:
29159668
15.

Transcutaneous glomerular filtration rate measurement in a canine animal model of chronic kidney disease.

Mondritzki T, Steinbach SML, Boehme P, Hoffmann J, Kullmann M, Schock-Kusch D, Vogel J, Kolkhof P, Sandner P, Bischoff E, Hüser J, Dinh W, Truebel H.

J Pharmacol Toxicol Methods. 2018 Mar - Apr;90:7-12. doi: 10.1016/j.vascn.2017.10.009. Epub 2017 Oct 31.

PMID:
29100965
16.

Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB Pathway.

Martínez-Martínez E, Buonafine M, Boukhalfa I, Ibarrola J, Fernández-Celis A, Kolkhof P, Rossignol P, Girerd N, Mulder P, López-Andrés N, Ouvrard-Pascaud A, Jaisser F.

Hypertension. 2017 Dec;70(6):1148-1156. doi: 10.1161/HYPERTENSIONAHA.117.09791. Epub 2017 Oct 23.

PMID:
29061727
17.

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.

Dutzmann J, Musmann RJ, Haertlé M, Daniel JM, Sonnenschein K, Schäfer A, Kolkhof P, Bauersachs J, Sedding DG.

PLoS One. 2017 Sep 19;12(9):e0184888. doi: 10.1371/journal.pone.0184888. eCollection 2017.

18.

Comments on: Lyubarova, R. and Gosmanova, E.O. Mineralocorticoid Receptor Blockade in End-Stage Renal Disease. Current Hypertension Reports, 2017. 19(5).

Gay A, Kolkhof P.

Curr Hypertens Rep. 2017 Aug 18;19(9):74. doi: 10.1007/s11906-017-0772-8. No abstract available.

PMID:
28822115
19.

Targeting of the Drosophila protein CG2254/Ldsdh1 to a subset of lipid droplets.

Thul PJ, Tschapalda K, Kolkhof P, Thiam AR, Oberer M, Beller M.

J Cell Sci. 2017 Sep 15;130(18):3141-3157. doi: 10.1242/jcs.199661. Epub 2017 Aug 3.

20.

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.

Kolkhof P, Bärfacker L.

J Endocrinol. 2017 Jul;234(1):T125-T140. doi: 10.1530/JOE-16-0600. Review.

21.

Comment on "New therapeutic agents in diabetic nephropathy".

Gay A, Kolkhof P.

Korean J Intern Med. 2017 May;32(3):569. doi: 10.3904/kjim.2017.137. Epub 2017 Apr 28. No abstract available.

22.

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.

Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, Bobadilla NA, Kolkhof P, Jaisser F, Barrera-Chimal J.

Hypertension. 2017 May;69(5):870-878. doi: 10.1161/HYPERTENSIONAHA.116.08526. Epub 2017 Mar 20.

PMID:
28320854
23.

Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1.

Barrera-Chimal J, André-Grégoire G, Nguyen Dinh Cat A, Lechner SM, Cau J, Prince S, Kolkhof P, Loirand G, Sauzeau V, Hauet T, Jaisser F.

J Am Soc Nephrol. 2017 Apr;28(4):1216-1226. doi: 10.1681/ASN.2016040477. Epub 2017 Jan 13.

24.

A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.

Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, Nowack C, Kolkhof P, Yamasaki Y; ARTS-DN Japan study group.

J Diabetes Complications. 2017 Apr;31(4):758-765. doi: 10.1016/j.jdiacomp.2016.11.021. Epub 2016 Dec 14.

25.

A Luciferase-fragment Complementation Assay to Detect Lipid Droplet-associated Protein-Protein Interactions.

Kolkhof P, Werthebach M, van de Venn A, Poschmann G, Chen L, Welte M, Stühler K, Beller M.

Mol Cell Proteomics. 2017 Mar;16(3):329-345. doi: 10.1074/mcp.M116.061499. Epub 2016 Dec 12.

26.

Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.

Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B.

Handb Exp Pharmacol. 2017;243:271-305. doi: 10.1007/164_2016_76. Review.

PMID:
27830348
27.

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.

Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B.

Eur Heart J. 2016 Jul 14;37(27):2105-14. doi: 10.1093/eurheartj/ehw132. Epub 2016 Apr 29.

28.

A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.

Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T, Kim SY, Nowack C, Kolkhof P, Shiga T; ARTS-HF Japan study group.

Circ J. 2016 Apr 25;80(5):1113-22. doi: 10.1253/circj.CJ-16-0122. Epub 2016 Apr 14.

29.

Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction.

Gueret A, Harouki N, Favre J, Galmiche G, Nicol L, Henry JP, Besnier M, Thuillez C, Richard V, Kolkhof P, Mulder P, Jaisser F, Ouvrard-Pascaud A.

Hypertension. 2016 Apr;67(4):717-23. doi: 10.1161/HYPERTENSIONAHA.115.06709. Epub 2016 Feb 22.

PMID:
26902493
30.

Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.

Grune J, Benz V, Brix S, Salatzki J, Blumrich A, Höft B, Klopfleisch R, Foryst-Ludwig A, Kolkhof P, Kintscher U.

J Cardiovasc Pharmacol. 2016 May;67(5):402-11. doi: 10.1097/FJC.0000000000000366.

PMID:
26859196
31.

Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628.

Ma FY, Han Y, Nikolic-Paterson DJ, Kolkhof P, Tesch GH.

PLoS One. 2015 Dec 23;10(12):e0145666. doi: 10.1371/journal.pone.0145666. eCollection 2015.

32.

Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia.

Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P, Jaisser F.

J Am Soc Nephrol. 2016 Feb;27(2):398-404. doi: 10.1681/ASN.2014121216. Epub 2015 Sep 11.

33.

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group.

JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.

PMID:
26325557
34.

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.

Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, Khan JA, Hillisch A, Lombès M, Rafestin-Oblin ME, Fagart J.

J Biol Chem. 2015 Sep 4;290(36):21876-89. doi: 10.1074/jbc.M115.657957. Epub 2015 Jul 22.

35.

Nonsteroidal antagonists of the mineralocorticoid receptor.

Kolkhof P, Nowack C, Eitner F.

Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24. doi: 10.1097/MNH.0000000000000147. Review.

PMID:
26083526
36.

Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.

Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, Eitner F, Albrecht-Küpper B, Schäfer S.

J Cardiovasc Pharmacol. 2014 Jul;64(1):69-78. doi: 10.1097/FJC.0000000000000091.

PMID:
24621652
37.

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.

Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F.

Eur Heart J. 2013 Aug;34(31):2453-63. doi: 10.1093/eurheartj/eht187. Epub 2013 May 27.

38.

Regulation of cyclic adenosine monophosphate release by selective β2-adrenergic receptor stimulation in human terminal failing myocardium before and after ventricular assist device support.

Kassner A, Toischer K, Bohms B, Kolkhof P, Abraham G, Hasenfuβ G, Morshuis M, Schulte Eistrup S, El-Banayosy A, Gummert J, Milting H.

J Heart Lung Transplant. 2012 Oct;31(10):1127-35. doi: 10.1016/j.healun.2012.07.005.

PMID:
22975104
39.

Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.

Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P.

ChemMedChem. 2012 Aug;7(8):1385-403. doi: 10.1002/cmdc.201200081. Epub 2012 Jul 12.

PMID:
22791416
40.

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.

Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F.

Eur J Heart Fail. 2012 Jun;14(6):668-75. doi: 10.1093/eurjhf/hfs061. Epub 2012 May 4.

41.

Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.

Kolkhof P, Borden SA.

Mol Cell Endocrinol. 2012 Mar 24;350(2):310-7. doi: 10.1016/j.mce.2011.06.025. Epub 2011 Jul 13. Review.

PMID:
21771637
42.

Dehydroepiandrosterone-induced phosphorylation and translocation of FoxO1 depend on the mineralocorticoid receptor.

Lindschau C, Kirsch T, Klinge U, Kolkhof P, Peters I, Fiebeler A.

Hypertension. 2011 Sep;58(3):471-8. doi: 10.1161/HYPERTENSIONAHA.111.171280. Epub 2011 Jul 11.

PMID:
21747041
43.

Identification of 4H,6H-[2]benzoxepino[4,5-c][1,2]oxazoles as novel squalene synthase inhibitors.

Griebenow N, Buchmueller A, Kolkhof P, Schamberger J, Bischoff H.

Bioorg Med Chem Lett. 2011 Jun 15;21(12):3648-53. doi: 10.1016/j.bmcl.2011.04.092. Epub 2011 Apr 29.

PMID:
21576018
44.

Identification and optimization of tetrahydro-2H-3-benzazepin-2-ones as squalene synthase inhibitors.

Griebenow N, Flessner T, Buchmueller A, Raabe M, Bischoff H, Kolkhof P.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2554-8. doi: 10.1016/j.bmcl.2011.02.004. Epub 2011 Feb 17.

PMID:
21396815
45.

Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.

Mondritzki T, Kolkhof P, Sabbah HN, Gheorghiade M, Fürstner C, Schmeck C, Siedentop H, Schaefer S, Truebel H.

Am J Ther. 2011 Jan;18(1):31-7. doi: 10.1097/MJT.0b013e3181f890ad.

PMID:
21192248
46.

Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats.

Schupp N, Kolkhof P, Queisser N, Gärtner S, Schmid U, Kretschmer A, Hartmann E, Oli RG, Schäfer S, Stopper H.

FASEB J. 2011 Mar;25(3):968-78. doi: 10.1096/fj.10-173286. Epub 2010 Dec 6.

PMID:
21135038
47.

Identification and optimization of substituted 5-aminopyrazoles as potent and selective adenosine A1 receptor antagonists.

Griebenow N, Bärfacker L, Meier H, Schneider D, Teusch N, Lustig K, Kast R, Kolkhof P.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5891-4. doi: 10.1016/j.bmcl.2010.07.095. Epub 2010 Aug 1.

PMID:
20728355
48.

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.

Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin ME, Kolkhof P.

J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.

49.

Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor.

Wunder F, Tinel H, Kast R, Geerts A, Becker EM, Kolkhof P, Hütter J, Ergüden J, Härter M.

Br J Pharmacol. 2010 May;160(2):399-409. doi: 10.1111/j.1476-5381.2010.00730.x.

50.

Cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes.

Kolkhof P, Geerts A, Schäfer S, Torzewski J.

Biochem Biophys Res Commun. 2010 Mar 26;394(1):233-9. doi: 10.1016/j.bbrc.2010.02.177. Epub 2010 Mar 3.

PMID:
20206126

Supplemental Content

Loading ...
Support Center